Physician profile
Rajesh Gopal
NPI 1003878869
$11,977.89
in general payments reported to CMS, 2019-2025
48 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,820 · 2020: $1,917 · 2021: $2,272 · 2022: $1,464 · 2023: $1,427 · 2024: $1,579 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,504.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,840.86 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,273.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,076.29 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,010.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $904.46 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $762.27 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $446.37 | 2019-2021 | |
| Abbvie INC. | $417.12 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $379.19 | 2022 | |
| Abbott Laboratories | $377.05 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $358.14 | 2020-2021 | |
| Pfizer INC. | $334.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $329.40 | 2019-2023 | Steglatro |
| Astellas Pharma US INC | $287.00 | 2020-2025 | Veozah, Myrbetriq |
| Eisai INC. | $255.93 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.